The stock of Radius Health Inc (NASDAQ:RDUS) is a huge mover today! About 469,456 shares traded hands. Radius Health Inc (NASDAQ:RDUS) has risen 73.37% since March 1, 2016 and is uptrending. It has outperformed by 64.13% the S&P500.
The move comes after 9 months positive chart setup for the $2.23 billion company. It was reported on Oct, 4 by Barchart.com. We have $87.40 PT which if reached, will make NASDAQ:RDUS worth $1.47 billion more.
Analysts await Radius Health Inc (NASDAQ:RDUS) to report earnings on November, 3. They expect $-1.04 EPS, down 52.94% or $0.36 from last year’s $-0.68 per share. After $-1.01 actual EPS reported by Radius Health Inc for the previous quarter, Wall Street now forecasts 2.97% negative EPS growth.
Radius Health Inc (NASDAQ:RDUS) Ratings Coverage
Out of 9 analysts covering Radius Health (NASDAQ:RDUS), 7 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 78% are positive. Radius Health has been the topic of 13 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The stock of Radius Health Inc (NASDAQ:RDUS) earned “Buy” rating by Canaccord Genuity on Thursday, September 24. As per Friday, May 6, the company rating was reinitiated by Cowen & Co. JP Morgan initiated the stock with “Overweight” rating in Friday, October 2 report. On Wednesday, February 24 the stock rating was downgraded by Jefferies to “Hold”. The rating was maintained by H.C. Wainwright on Wednesday, September 21 with “Buy”. Deutsche Bank initiated the stock with “Buy” rating in Friday, August 14 report. H.C. Wainwright initiated it with “Buy” rating and $55 target price in Monday, May 23 report. As per Wednesday, March 30, the company rating was initiated by Goldman Sachs.
According to Zacks Investment Research, “Radius Health Inc. is a science-driven biopharmaceutical company. It is focused on developing novel differentiated therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases. The Company’s lead product candidate, abaloparatide (BA058), is in development, in both injection (Abaloparatide-SC) and transdermal (Abaloparatide-TD) methods of administration, for the prevention of fractures in post-menopausal women at risk of fracture from osteoporosis. Radius Health Inc. is based in Cambridge, Massachusetts.”
Insitutional Activity: The institutional sentiment increased to 1.32 in Q2 2016. Its up 0.03, from 1.29 in 2016Q1. The ratio increased, as 20 funds sold all Radius Health Inc shares owned while 33 reduced positions. 22 funds bought stakes while 48 increased positions. They now own 42.68 million shares or 5.94% more from 40.29 million shares in 2016Q1.
Fiera Cap accumulated 0.12% or 574,077 shares. Citadel Limited Liability Company has invested 0.03% of its portfolio in Radius Health Inc (NASDAQ:RDUS). The Illinois-based Nuveen Asset Ltd Co has invested 0.01% in Radius Health Inc (NASDAQ:RDUS). Ameriprise Fincl accumulated 41,981 shares or 0% of the stock. Dimensional Fund Advsrs Lp, a Texas-based fund reported 11,514 shares. State Board Of Administration Of Florida Retirement Systems owns 21,248 shares or 0% of their US portfolio. Farallon Mngmt Lc holds 0.78% of its portfolio in Radius Health Inc (NASDAQ:RDUS) for 1.54 million shares. Bank & Trust Of America Corp De holds 0% or 274,068 shares in its portfolio. The New York-based New York State Common Retirement Fund has invested 0% in Radius Health Inc (NASDAQ:RDUS). Tiaa Cref Management Limited Liability holds 0% or 108,961 shares in its portfolio. Alps Advsr Incorporated last reported 0.02% of its portfolio in the stock. Vanguard Gru has invested 0.01% of its portfolio in Radius Health Inc (NASDAQ:RDUS). Ladenburg Thalmann Financial Inc last reported 0% of its portfolio in the stock. Global X Mgmt Ltd owns 124 shares or 0% of their US portfolio. Ubs Asset Mngmt Americas Inc has 20,028 shares for 0% of their US portfolio.
More recent Radius Health Inc (NASDAQ:RDUS) news were published by: Fool.com which released: “Why Radius Health Inc. is Screaming Higher Today” on February 22, 2016. Also Fool.com published the news titled: “Why Radius Health Inc. Dropped 45% in January” on February 08, 2016. Philly.com‘s news article titled: “Radius Health eyes drug launch, expands in Wayne” with publication date: June 22, 2016 was also an interesting one.
RDUS Company Profile
Radius Health, Inc. is a biopharmaceutical firm focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis. The Company’s clinical pipeline also includes an investigational abaloparatide transdermal patch for use in osteoporosis and the investigational drug RAD1901 for use in hormone-driven and hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. The Company’s preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for use in cancer.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.